A detailed history of Mbm Wealth Consultants, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Mbm Wealth Consultants, LLC holds 2,540 shares of VRTX stock, worth $1.21 Million. This represents 0.38% of its overall portfolio holdings.

Number of Shares
2,540
Previous 2,381 6.68%
Holding current value
$1.21 Million
Previous $1.12 Million 5.82%
% of portfolio
0.38%
Previous 0.39%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

BUY
$460.0 - $505.78 $73,140 - $80,419
159 Added 6.68%
2,540 $1.18 Million
Q2 2024

Jul 30, 2024

SELL
$392.81 - $485.53 $27,103 - $33,501
-69 Reduced 2.82%
2,381 $1.12 Million
Q1 2024

Apr 18, 2024

BUY
$407.69 - $446.08 $33,430 - $36,578
82 Added 3.46%
2,450 $1.02 Million
Q4 2023

Jan 30, 2024

BUY
$343.0 - $410.68 $30,527 - $36,550
89 Added 3.91%
2,368 $963,000
Q3 2023

Oct 19, 2023

BUY
$338.18 - $362.46 $27,392 - $29,359
81 Added 3.69%
2,279 $792,000
Q2 2023

Jul 24, 2023

BUY
$314.42 - $351.91 $131,113 - $146,746
417 Added 23.41%
2,198 $773,000
Q4 2022

Feb 15, 2023

BUY
$285.76 - $321.48 $194,602 - $218,927
681 Added 61.91%
1,781 $509,000
Q3 2022

Oct 24, 2022

SELL
$273.83 - $305.53 $44,360 - $49,495
-162 Reduced 12.84%
1,100 $327,000
Q2 2022

Aug 15, 2022

BUY
$234.96 - $292.55 $11,278 - $14,042
48 Added 3.95%
1,262 $356,000
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $7,528 - $8,872
-34 Reduced 2.72%
1,214 $317,000
Q4 2021

Feb 15, 2022

BUY
$177.01 - $223.45 $21,241 - $26,814
120 Added 10.64%
1,248 $274,000
Q3 2021

Nov 16, 2021

BUY
$181.39 - $202.99 $27,934 - $31,260
154 Added 15.81%
1,128 $205,000
Q2 2021

Aug 13, 2021

BUY
$187.49 - $221.1 $29,623 - $34,933
158 Added 19.36%
974 $197,000
Q1 2021

May 10, 2021

BUY
$207.02 - $241.31 $48,235 - $56,225
233 Added 39.97%
816 $175,000
Q4 2020

Feb 09, 2021

BUY
$207.01 - $276.09 $120,686 - $160,960
583 New
583 $138,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Mbm Wealth Consultants, LLC Portfolio

Follow Mbm Wealth Consultants, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mbm Wealth Consultants, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mbm Wealth Consultants, LLC with notifications on news.